ICON, an Accredited Member Organisation of the Indian Society for Clinical Research (ISCR), recently participated in the 17th annual ISCR conference, held February 1-3 in Hyderabad, India. This conference serves as a pivotal forum for professionals engaged in clinical research activities across India, fostering knowledge exchange and learning opportunities to further drive industry progress. With over 1,800 delegates representing major international and national pharma companies, global CROs and technology companies, the event showcased the extensive capabilities of all clinical research domains in India.
Transforming clinical research: The conference theme
The central theme of this year’s conference was "Transformation in clinical research for better patient outcomes." Spanning six major tracks, including Clinical Operations, Regulatory Affairs, Biostatistics and Programming, Clinical Data Management, Pharmacovigilance, Real-World Evidence (RWE) and Health Outcome Economic Research (HOER), the event explored various facets of this transformation. Discussions ranged from decentralised clinical trials to the impact of technology on the clinical research landscape.
Focus on Clinical Data Management and Biostatistics and Programming
Of particular interest were the sessions within the Clinical Data Management and Biostatistics and Programming tracks. These sessions delved into the digital transformation and automation in clinical data management, and biostatistics and programming, emphasising its role in accelerating clinical research and enhancing patient outcomes.
ICON’s industry-leading insights
ICON, with our extensive experience in digital transformation, data management, and biostatistics and programming, shared valuable insights during the conference. Our subject matter experts and thought leaders presented on topics of special interest, including:
Digital transformation and clinical data management:
Kedar Deshmukh, Director, Clinical Data Science
Panel discussion: Digital health technologies (DHT) and decentralised clinical trials’ impact on patient outcomes
The potential of digital health technologies (DHT) extends beyond exploratory outcomes, particularly in driving digital endpoints. There is a pressing need for clearly defined primary and secondary digital endpoints, especially in neurology and cardiovascular therapeutic areas. Evidence is mounting that wearable sensors offer significant potential for gathering continuous, high-frequency and detailed endpoint data, providing a comprehensive view for improved clinical evaluation. However, wearable sensors face challenges in patient authentication and data accuracy, leading to regulatory hurdles in accepting digital endpoints.
Clinical data management must collaborate with clinical data systems technology to develop advanced algorithms that ensure patient authentication and identify data patterns that may arise from improper use, external influences causing false positives or false negatives, or simply missing data due to synchronisation issues.
Emerging roles such as decentralised clinical trial (DCT) experts, DHT leads and concierge service leads play a crucial role in implementing patient-facing technologies with trial subjects and enhancing compliance and retention.
Shalima James, Clinical Data Science Lead
Demystifying the clinical data science puzzle
Clinical Data Science is an emerging field within clinical research that demands multidisciplinary expertise. The necessity for comprehensive and standardised data is paramount. Data quality now encompasses more than just the quality of Electronic Data Capture (EDC) source data or reconciliations; it also involves the quality of data ingestion and the review of data patterns.
The development of validated AI models is essential to establish trust among clinicians. Collaboration between data scientists and clinicians is crucial. Both parties must understand each other's expertise and collaborate to define research questions, validate insights and implement data-driven interventions.
Suvarchala Nidhanapati, Senior Clinical Data Science Lead
Evolution of clinical data review and roles to enhance subject safety outcomes
Technological advancements have significantly transformed data review methodologies, leading to the emergence of diverse roles and responsibilities. According to the ICH GCP E6 R2 guidelines, data science plays a pivotal role in this transformation process. New roles, such as data scientists, have evolved by amalgamating traditional data management responsibilities with expertise in data science. These professionals have contributed significantly to the development of innovative approaches for safety data review.
Real-time data review for safety and vendor data has enabled the early identification of potential risks, thereby enhancing safety measures and reducing the time required for critical data analysis.
Biostatistics and Programming:
Smitha Nalam, Director, Statistical Programming
Panel discussion: Are new technologies (AI/ML/IOT) a threat or blessing for Biostatisticians and Statistical Programmers?
This discussion around the shifting innovation in artificial intelligence (AI) and machine learning (ML) in Biostatistics and Programming shed light on how individuals with domain expertise can easily adapt into newer roles. The panellists shared new ideas and techniques for innovative data sources and, reminiscent of complex data standardisation, the exploration of new technologies in analysis and statistics that could help bring solutions to patients faster and meet unmet medical needs.
Supratik Chakravarthy, Principal Biostatistician
Picture perfect: Exploring distinctive visualisation techniques in clinical trials
Effective data visualisation techniques play a crucial role in transforming complex data into understandable visual representations, facilitating the faster and more effective identification of patterns, trends and anomalies. We explored examples of unique visualisation techniques based on different types of data scenarios and discussed the importance of these advancements for expanding medical knowledge and improving patient outcomes.
Conclusion
The ISCR conference served as a catalyst for fostering collaboration and innovation in India's clinical research landscape. The event spotlighted India’s remarkable surge in clinical research activities, highlighting collaborative efforts among government bodies, pharmaceutical companies and research institutions. We are proud to have contributed to this event and remain committed to advancing the field amidst its evolving landscape.
Contact us for further insights or to discover how ICON can support your clinical data management and biostatistics needs. We look forward to partnering with you on your journey toward better patient outcomes.
Authors:
![](https://icon.widen.net/content/543b26c3-3031-47a1-92a7-78119edd742b/web/Kedar_Deshmukh.png?crop=yes&w=240&h=240&itok=KZ3kqVRL)
Kedar Deshmukh
![](https://icon.widen.net/content/373f06e5-dfac-4258-b6b6-da23bfb2b762/web/Smitha_Nalam.png?crop=yes&w=240&h=240&itok=HyjeTcZY)
Smitha Nalam
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel